P/B
3
Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
$3.7B
Market Cap • 10/2/2026
1996
(30 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
Canada
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
12,8
EPS
—
Market Cap
Market Cap
3,7B
EV
2,8B
EV/Revenue
0
EV/EBITDA
-6,3
EV/EBIT
-6,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-26%
Total Yield
-26%
Payout
0%
Retained Earnings
-1,5B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
42%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
48,5%
CAGR Net Income 5Y
47,3%
CAGR EPS 5Y
25,5%
CAGR OCF 5Y
42,2%
Leverage
N.D./EBITDA
2,1
Debt/Equity
0%
Current Ratio
21
Quick Ratio
20,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!